Lipoprotein-associated phospholipase A2: A cardiovascular risk predictor and a potential therapeutic target

Future Cardiology

Volumn 5, Issue 2, 2009, Pages 159-173

  Ali, Muzammil ^a   Madjid, Mohammad ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; High density lipoproteins; Lipoprotein associated phospholipase; Low density lipoproteins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; BIOLOGICAL MARKER; DARAPLADIB; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2 INHIBITOR; PLACEBO; PRAVASTATIN;

ACUTE CORONARY SYNDROME; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE MARKER; DNA POLYMORPHISM; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME RELEASE; GENE EXPRESSION; GENE STRUCTURE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 67049172713     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.5.2.159     Document Type: Review

References (142)

1. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P: Phospholipase A(2) in vascular disease. Circ. Res. 89, 298-304 (2001).
2. Tjoelker LW, Wilder C, Eberhardt C et al.: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374, 549-553 (1995).
3. Tew DG, Southan C, Rice SQ et al.: Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phosholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 16, 591-599 (1996).
4. Arai H: Platelet-activating factor acetylhydrolase. Prostaglandins Other Lipid Mediat. 68-69, 83-94 (2002).
5. Schaloske RH, Dennis EA: The phospholipase A2 superfamily and its group numbering system. Biochem. Biophys. Acta 1761, 1246-1259 (2006).
6. Tselepis AD, John Chapman M: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2 platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 3, 57-68 (2002),
7. MacPhee CH, Moores KE, Boyd HF et al.: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase. generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338 (Pt 2), 479-487 (1999).
8. Khan BV, Parthasarathy SS, Alexander RW, Medford RM: Modified low density lipoprorein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J. Clin. Invest. 95, 1262-1270 (1995).
9. McConnell JP, Hoefner DM: Lipoprotein-associated phospholipase A2. Clin. Lab. Med. 26, 679-697 (2006).
10. Shi Y, Zhang P, Zhang L et al.: Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 191, 54-62 (2007).
11. Chen L, Liang B, Froese DE et al.: Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J. Lipid Res. 38, 546-553 (1997).
12. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A: Structural differences in the ability of lysophospholipids to inhibit endothelium-dependent hyperpolarization by acetylcholine in rat mesenteric arteries. Biochem. Biophys. Res, Commun. 227, 479-483 (1996).
13. Kume N, Gimbrone MA Jr: Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J. Clin. Invest. 93, 907-911 (1994).
14. Takahara N, Kashiwagi A, Maegawa H, Shigeta Y: Lysophosphatidylcholine stimulates the expression and production ofMCP-1 by human vascular endothelial cells. Metabolism 45, 559-564 (1996).
15. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K: Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 161, 387-394 (2002).
16. Wong JT, Tran K, Pierce GN, Chan AC, Karmin O, Choy PC: Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. J. Biol. Chem. 273, 6830-6836 (1998).
17. Zhu Y, Lin JH, Liao HL, Verna L, Stemerman MB: Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim. Biophys. Acta 1345, 93-98 (1997).
18. Carpenter KL, Dennis IF, Challis IR et al.: Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett. 505, 357-363 (2001).
19. Chai YC, Howe PH, DiCorleto PE, Chisolm GM: Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J. Biol. Chem. 271, 17791-17797 (1996).
20. Kohno M, Yokokawa K, Yasunari K et al.: Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98, 353-359 (1998).
21. Liu-Wu Y, Hurt-Camejo E, Wiklund O: Lysophosphatidylcholine induces the production of IL-1β by human monocytes. Atherosclerosis 137, 351-357 (1998).
22. McMurray HE, Parthasarathy S, Steinberg D: Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Invest. 92, 1004-1008 (1993).
23. Oestvang J, Anthonsen MW, Johansen B: Role of secretory and cytosolic phospholipase A(2) enzymes in lysophosphatidylcholine-stimulated monocyte arachidonic acid release. FEBS Lett. 555, 257-262 (2003).
24. Rikitake Y, Kawashima S, Yamashita T et al.: Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. Arterioscler. Thromb. Vasc. Biol. 20, 1006-1012 (2000).
25. Yamakawa T, Tanaka S, Yamakawa Y et al.: Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 22, 752-758 (2002).
26. Macphee CH: Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease ancla therapeutic target. Curr. Opin. Pharmacol. 1, 121-125 (2001).
27. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM: Human macrophages secret platelet-activating factor acetylhydrolase. J. Biol. Chem. 265, 9682-9687 (1990).
28. Narahara H, Johnston JM: Smoking and preterm labor: effect of a cigarette smoke extract on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages. Am. J. Obstet. Gynecol. 169, 1321-1326 (1993).
29. Narahara H, Johnston JM: Effects of endotoxins and cytokines on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages. Am. J. Obstet. Gynecol. 169, 531-537 (1993).
30. Dupuis F, Denizot Y, Fixe P, Dulery C, Praloran V: PAF and haematopoiesis. X. Macrophage colony-stimulating factor and granulocyte, macrophage colony-stimulating factor enhance platelet-activating factor acetylhydrolase production by human blood-derived macrophages. Biochim. Biophys. Acta 1311, 27-32 (1996).
31. Watanabe J, Marathe GK, Neilsen PO et al.: Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J. Biol. Chem. 278, 33161-33168 (2063).
32. Memon RA, Staprans I, Noor M et al.: Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 20, 1536-1542 (2000).
33. Memon RA, Fuller J, Moser AH, Feingold KR, Grunfeld C: In vivo regulation of plasma platelet-activating factor acetylhydrolase during the actite phase response. Am. J. Physiol. 277, R94-103 (1999).
34. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM: A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 38, 1302-1306 (2001).
35. Blencowe C, Hermetter A, Kostner GM, Deigner HP: Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J. Biol. Chem. 270, 31151-31157 (1995).
36. Karabina SA, Elisaf MC, Goudevenos J, Siamopoulos KC, Sideris D, Tselepis AD: PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro. Atherosclerosis 125, 121-134 (1996).
37. Stafforini DM, Tjoelker IW, McCormick SP et al.: Molecular basis of the interaction between plasma platelet-activating factor acerylhydrolase and low density lipoprotein. J. Biol. Chem. 274, 7018-7024 (1999).
38. Stafforini DM, McIntyre TM, Carter ME Prescott SM: Human plasma platelet-activating (actor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262, 4215-4222 (1987).
39. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC: Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J. Lipid Res. 38, 2281-2288 (1997).
40. Tsimihodimos V, Karabina SA, Tambaki AP et al.: Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 43, 256-263 (2002).
41. Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ: Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 37, 12867-12874 (1998).
42. De Castellarnau C, Sanchez-Quesada JL, Benitez S et al.: Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20, 2281-2287 (2000).
43. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11, 298-306 (1991).
44. Chen CH, Jiang T, Yang JH et al.: Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 107, 2102-2108 (2003).
45. Yang CY, Raya JL, Chen HH et al.: Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 23, 1083-1090 (2003).
46. Chen CH, Poucher SM, Lu. J, Henry PD: Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr. Vasc. Pharmacol. 2, 33-43 (2004).
47. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI: Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354, 1-7 (2001).
48. Aron L, Jones S, Fielding CJ: Human plasma lecithin-cholesterol acyltransferase. Characterization of cofactor-dependent phospholipase activity. J. Biol. Chem. 253, 7220-7226 (1978).
49. Lia M, Subbalah PV: Hydrolysis and transesterification of plalelet-activating factor by lecithin-cholesterol acyltransferase. Proc. Natl Acad. Sci. USA 91, 6035-6039 (1994).
50. Quarck R, De Geest B, Stengel D et al.: Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103, 2495-2500 (2001).
51. -/- mice. FASEB J. 14, 2032-2039 (2000).
52. Turunen P, Jalkanen J, Heikura T et al.: Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro. J. Lipid Res. 45, 1633-1639 (2004).
53. Turunen P, Puhakka H, Rutanen J et al.: Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis 179, 27-33 (2005).
54. Collins T, Cybulsky MI: NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest. 107, 255-264 (2001).
55. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ: Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques, Proc. Natl Acad. Sci. USA 101, 11779-11784 (2004).
56. Arakawa H, Qian JY, Baatax D et al.: Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits. Circulation 111, 3302-3309 (2005).
57. Morgan EN, Boyle EM Jr, Yun W et al.: Platelet-activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 100, II365-II368 (1999).
58. Marathe GK, Zimmerman GA, McIntyre TM: Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278, 3937-3947 (2003).
59. Caslake MJ, Packard CJ: Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease, Curr. Opin. Lipidol. 14, 347-352 (2003).
60. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH: Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150, 413-419 (2000).
61. Zalewski A, Macphee C: Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol. 25, 923-931 (2005).
62. Hakkinen T, Luoma. JS, Hiltunen MO et al.: Lipoprotein-Associated Phospholipase A2, Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions. Arterioscler. Thromb. Vasc. Biol. 19, 2909-2917 (1999).
63. Macphee CH, Nelson JJ, Zalewski A: Lipoprotein-associated phospholipase A2 as a target of therapy. Curr. Opin. Lipidol. 16, 442-446 (2005).
64. Rikitake Y, Hirata K, Yamashita T et al.: Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 22, 2049-2053 (2002).
65. Kolodgie FD, Burke AP, Skorija KS et al.: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2523-2529 (2006).
66. Aprahamian T, Rifkin I, Bonegio R et al.: Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease. J. Exp. Med. 199, 1121-1131 (2004).
67. Carpenter KL, Challis IR, Arends MJ: Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPARgamma. FEBS Lett. 553, 145-150 (2003).
68. Kadl A, Bochkov VN, Huber J, Leitinger N: Apoptotic cells as sources for biologically active oxidized phospholipids. Antioxid. Redox Signal 6, 311-320 (2004).
69. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, Martinet W: Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256-1261 (2005).
70. Stafforini DM, Sheller JR, Blackwell TS et al.: Release of free F2-isoprostanes from esterified phospholipids is catalyzed by v intracellular and plasma platelet-activating factor acetylhydrolases. J. Biol. Chem. 281, 4616-4623 (2006).
71. Fam SS, Morrow JD: The isoprostanes: unique products of arachidonic acid oxidation-a review. Curr. Med. Chem. 10, 1723-1740 (2003).
72. Morrow JD: Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25, 279-286 (2005).
73. Pratico, D, Iuliano L, Mauriello A et al.: Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100, 2028-2034 (1997).
74. Nishi E, Kurne N, Ochi H et al.: Lysophosphatidylcholine increases expression of hepafin-binding epidermal growth factor-like growth factor in human T lymphocytes. Circ. Res. 80, 638-644 (1997).
75. Sakai M, Miyazaki A, Hakamata H, Kobori S, Shichiri M, Horiuchi S: Endocytic uptake of lysophosphatidylcholine mediated by macrophage scavenger receptor plays a major role in oxidized low density lipoprotein-induced macrophage growth. J. Atheroscler. Thromb. 2, 81-86 (1996).
76. Yokote K, Morisaki N, Zenibayashi M et al.: The phospholipase-A2 reaction leads to increased monocyte adhesion of endothelial cells via the expression of adhesion molecules. Eur. J. Biochem. 217, 723-729 (1993).
77. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344, 160-162 (1990).
78. Liu SY, Lu X, Choy S et al.: Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc. Res. 28, 1476-1481 (1994).
79. Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R: Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc. Natl Acad. Sci. USA 91, 1069-1073 (1994).
80. Morimoto M, Kume N, Miyamoto S et al.: Lysophosphatidylcholine induces early growth response factor-1 expression and activates the core promoter of PDGF-A chain in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21, 771-776 (2001).
81. Safaya R, Chai H, Kougias P et al.: Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J. Surg. Res. 126, 182-188 (2005).
82. Inoue N, Takeshita S, Gao D et al.: Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 155, 45-52 (2001).
83. Wilensky RL, Shi Y, Mohler ER 3rd et al.: Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14, 1059-1066 (2008).
84. Eizawa H, Yui Y, Inoue R et al.: Lysophosphatidylcholine inhibits endothelium-dependent hyperpolarization and N omega-nitro-L-arginine/indomethacin-resistant endothelium-dependent relaxation in the porcine coronary artery. Circulation 92, 3520-3526 (1995).
85. Boekholdt SM, Keller TT, Wareham NJ et al.: Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler. Thromb. Vasc. Biol. 25, 839-846 (2005).
86. Fichtlscherer S, Kaszkin M, Breuer S, Dimmeler S, Zeiher AM: Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function inp atients with coronary artery disease. Clin. Sci. (Lond.) 106, 511-517 (2004).
87. Rice SQ, Southan C, Boyd HF et al.: Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor. Biochem. J. 330 (Pt 3), 1309-1315 (1998).
88. Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, Claesson HE: Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler. Thromb. Vasc. Biol. 17, 2257-2263 (1997).
89. Winkler K, Hoffmann MM, Winkelmann BR et al.: Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established rok factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin. Chem. 53, 1440-1447 (2007).
90. Kiechl S, Willeit J, Mayr M et al.: Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27, 1788-1793 (2007).
91. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E: Lipoprotein-associated phospholipase A2 is ah independent predictor of incident coronary heart disease in an apparently-healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol. 51, 913-919 (2008).
92. Raichlin E, McConnell TP, Bae JH, Kremers WK, Lerman A, Frantz RP: Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients, Transplantation 85, 963-968 (2008).
93. Gerber Y, Durday SM, Jaffe AS et al.: Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the community. Atherosclerosis (2008).
94. Packard CJ, O'Reilly DS, Caslake MJ et al.: Lipoprotein-associated phospholipase A2 as an independent predictor ofcoronary heart disease. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 343, 1148-1155 (2000).
95. Ballantyne CM, Hoogeveen RC, Bang H et al.: Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Riskin Communities (ARIC) Study. Arch. Intern. Med. 165, 2479-2484 (2005).
96. Oei HH, van der Meer IM, Hofman A et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111, 570-575 (2005).
97. Winkler K, Winkelmann BR, Scharnagl H et al.: Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors: The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111, 980-987 (2005).
98. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF: Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler. Thromb. Vasc. Biol. 28, 1172-1178 (2008).
99. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM: Distribution and correlates of lipoprotein-associated phospholipase A2. in au elderly cohort: the Cardiovascular Health Study. J. Am. Geriatr. Soc. 56, 792-799 (2008)
100. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL: High-sensitiviiy C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch. Intern. Med. 166, 2073-2080 (2006).
101. May HT, Horné BD, Anderson JL et al.: Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am. Heart J. 152, 997-1003, (2006).
102. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur. Heart J. 26, 137-144 (2005).
103. Khuseyinova N, Imhof A, Rothenbacher D et al.: Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 182, 181 (2005).
104. Ballantyne CM, Hoogeveen RC, Bang H et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart-disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109, 837-842 (2004).
105. Koenig W, Twardella D, Brenner H, Rotheribacher D: Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler. Thromb. Vasc. Biol. 26, 1586-1593 (2006).
106. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE: High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin. Chem. 52, 1331-1338 (2006).
107. Mockel M, Muller R, Vollert JO et al.: Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin. Res. Cardiol. 96, 604-612 (2007).
108. Oldgren J, James SK, Siegbahn A, Wallenrin L: Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur. Heart J. 28, 699-704 (2007).
109. Kardys I, Oei H-HS, van der Meer IM, Hofman A, Breteler MMB, Witteman JCM: Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: The Rotterdam Study. Arterioscler. Thromb. Vasc, Biol. 26, 631-636 (2006).
110. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM: Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler. Thromb. Vasc. Biol. 25, 216-221 (2005).
111. Kiortsis DN, Tsouli S, Lourida ES et al.: Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 56, 451-458 (2005).
112. Folsom AR, Chambless LE, Ballantyne CM et al.: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: The Atherosclerosis Risk in Communities Study. Arch. Intern. Med. 166, 1368-1373 (2006).
113. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL: Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler. Thromb. Vasc. Biol. 26, 2517-2522 (2006).
114. Anderson JL: Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am. J. Cardiol. 101, 23F-33F (2008).
115. Albert MA, Glynn RJ, Wolfert RL, Ridker PM: The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis 182, 193 (2005).
116. Muhlestein JB, May HT, Jensen JR et al.: The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia: The DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study. J. Am. Coll. Cardiol. 48, 396 (2006).
117. O'Donoghue M, Morrow DA, Sabatine MS et al.: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 113, 1745-1752 (2006).
118. Schaefer EJ, McNamara JR, Asztalos BF, et al.: Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am. J. Cardiol. 95, 1025-1032 (2005).
119. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W: Fluvastatin slow-release lowers platelet-activating factor acetylhydrolase activity: a placebo-controlled trial in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 1153-1159 (2004).
120. Saougos VG, Tambaki AP, Kalogirou M et al.: Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 27, 2236-2243 (2007).
121. Kom GD, Schwedhelm E, Maas R, Schneider L, Benndorf R, Boger RH: Impact of atorvastatin treatment on platelet-activating factor acerylhrydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients. Br. J. Clin. Pharmacol. 63, 672-679 (2007).
122. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD: Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem. 51, 2264-2273 (2005).
123. Lp-PLA2: a new marker of vascular risk. Med. Lett. Drugs Ther. 45, 83 (2003).
124. FDA approves test for heart-disease marker. Health News 9, 10 (2003).
125. New test predicts heart risk. FDA Consum. 37, 6 (2003).
126. Davidson MH, Corson MA, Alberts MJ et al.: Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am. J. Cardiol. 101, 5IF-57F (2008).
127. Wolfert RL: Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk. Presented at: American Heart Association. November 2004 New Orleans, LA, USA.
128. Khuseyinova N, Greven S, Ruckerl R et al.: Variability of serial lipoprotein-associated phospholipase A2 measurements in post myocardial infarction patients: results from the AIRGENE Study Center Augsburg. Clin. Chem. 54, 124-130 (2008).
129. Kruse S, Mao XQ, Heinzmann A et al.: The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalyrical activities and are associated with atopy and asthma. Am. J. Hum. Genet. 1522-1530 (2000).
130. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M: Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150, 209-216 (2000).
131. Unno N, Nakamura T, Kaneko H et al.: Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. J. Vasc. Surg. 32, 263-267 (2000).
132. Yamada Y, Ichihara S, Fujimura T, Yokota M: Identification of the G994-> T missense in exon 9 of the plasma platelet-activating factor acerylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 47, 177-181 (1998).
133. Ichihara S, Yamada Y, Yokota M: Association of a G994-> T missense mutation in the plasma, platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. Circulation 98, 1881-1885 (1998).
134. Ishihara M, Iwasaki T, Nagano M et al.: Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. J. Hum. Genet. 49, 302-307 (2004).
135. Abuzeid AM, Hawe E, Humphries SE, Talmud PJ: Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 168, 283-288 (2003).
136. Ninio E, Tregouet D, Carrier J-L et al.: Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum. Mat Genet. 13, 1341-1351 (2004).
137. Hoffmann MM, Winkler K, Renner W et al.: Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk ind Cardiovascular Health Study). J. Thromb. Haemost. (2008).
138. Asztalos BF, Le Maulf F, Dallal GE et al.: Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am. J. Cardiol. 99, 681-685 (2007).
139. Booker ML: Lp-PLA2 inhibitors (GlaxoSmithKline). IDrugs 4, 1173-1177 (2001).
140. Blackie JA, Bloomer JC, Brown MJ et al.: The identification of clinical candidate SB-4808418: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg. Med. Chem. Lett. 13, 1067-1070 (2003).
141. Mohler ER 3rd, Ballantyne CM, Davidson MH et al.: The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with s coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 51, 1632-1641 (2008).
142. Serruys PW, Garcia-Garcia HM, Buszman P et al.: Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172-1182 (2008).